Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2012 Mar 15.

Published in final edited form as: Clin Cancer Res. 2010 Dec 7;17(6):1351–1361. doi: 10.1158/1078-0432.CCR-10-1905

Growth of MCF7/HER2-18 xenograft tumors in athymic female mice treated with variable anti-HER single agents and combinations, with or without ER targeted therapy. A. E2 treatment alone or with lapatinib (E2+L), trastuzumab (E2+T), or their combination (E2+L+T). B. Tamoxifen treatment alone or lapatinib (Tam+L), trastuzumab (Tam+T), or their combination (Tam+L+T). C. Tamoxifen treatment in the presence of estrogen with the combination of lapatinib and (E2+Tam+L+T). D. Estrogen deprivation (ED) alone or along with lapatinib (ED+L), trastuzumab (ED+T), or their combination (ED+L+T). Results are presented as the mean tumor volume; error bars represent the standard error. In panels B, C, D, and E, for each group, the number of mice with complete tumor regression and the total number of mice are shown. E. Tamoxifen treatment with alternative combinations of HER family inhibitors—lapatinib and gefitinib (Tam+L+G), double dose lapatinib 200mg/kg/day (Tam+2L), and tamoxifen with lapatinib and pertuzumab (Tam+L+P). Complete regression was defined as complete tumor regression documented on 3 consecutive weekly measurements.

Growth of MCF7/HER2-18 xenograft tumors in athymic female mice treated with variable anti-HER single agents and combinations, with or without ER targeted therapy. A. E2 treatment alone or with lapatinib (E2+L), trastuzumab (E2+T), or their combination (E2+L+T). B. Tamoxifen treatment alone or lapatinib (Tam+L), trastuzumab (Tam+T), or their combination (Tam+L+T). C. Tamoxifen treatment in the presence of estrogen with the combination of lapatinib and (E2+Tam+L+T). D. Estrogen deprivation (ED) alone or along with lapatinib (ED+L), trastuzumab (ED+T), or their combination (ED+L+T). Results are presented as the mean tumor volume; error bars represent the standard error. In panels B, C, D, and E, for each group, the number of mice with complete tumor regression and the total number of mice are shown. E. Tamoxifen treatment with alternative combinations of HER family inhibitors—lapatinib and gefitinib (Tam+L+G), double dose lapatinib 200mg/kg/day (Tam+2L), and tamoxifen with lapatinib and pertuzumab (Tam+L+P). Complete regression was defined as complete tumor regression documented on 3 consecutive weekly measurements.